EVMN Evommune, Inc.

NYSE
$14.65

Evommune, Inc. (EVMN) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.82 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +6.9% since its last earnings release on August 6, 2026.

Evommune Missed Consensus Estimates
Thursday, August 6, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($0.82)
Rev est $3M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $14.20

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Evommune, Inc.

Evommune Inc. is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. Evommune Inc. is based in PALO ALTO, Calif.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow